Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits
Portfolio Pulse from Vandana Singh
Merck & Co Inc (NYSE:MRK) secured a legal victory as the 3rd U.S. Circuit Court of Appeals upheld the dismissal of nearly 1,200 lawsuits related to its Zostavax shingles vaccine. The court ruled that the plaintiffs failed to provide required clinical test results. MRK stock is down 2.18% at $123.14.
July 18, 2024 | 6:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck & Co Inc (NYSE:MRK) achieved a significant legal victory as the 3rd U.S. Circuit Court of Appeals upheld the dismissal of nearly 1,200 lawsuits concerning its Zostavax shingles vaccine. Despite this, MRK stock is down 2.18%.
The legal victory removes a significant overhang of litigation risk for Merck, which is positive for the company. However, the stock is currently down, possibly due to broader market conditions or other factors. In the short term, the legal win should provide a positive sentiment boost.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100